Cohance Lifesciences, formerly Suven Pharmaceuticals, has reported a 12.9% sequential increase in revenue from operations to Rs. 476.7 crore for the second quarter ended September 30, 2026, signalling an improvement in its business trajectory.
However, revenue remained 14.2% lower year-on-year.
The global contract development and manufacturing organisation (CDMO) reported an adjusted EBITDA of Rs. 45.8 crore for Q2 FY27, with the adjusted EBITDA margin improving to 10%, compared with 2.2% in the preceding quarter.
Gross margin, however, came under pressure, declining to 70.8% from 74.6% in Q2 FY26, primarily due to an unfavourable business and product mix.
For the first half of FY27, revenue from operations stood at Rs. 898.9 crore, down 18.6% year-on-year. Gross margin declined to 71.1%, compared with 73.8% in the corresponding period last year. Adjusted EBITDA for the half year was Rs. 55.1 crore, translating into a margin of 6.1%.
Looking ahead, the company expects a stronger second half, projecting year-on-year growth in both revenue and EBITDA, backed by improving business visibility.
Umang Vohra, Executive Chairman and Group CEO, said: “Q2 reflects an improving business trajectory and the broader Cohance platform beginning to come together. We expect H2 to be materially stronger than H1, with year-on-year growth in both revenue and EBITDA, supported by improving visibility across our businesses.
"At the same time, we remain focused on progressing our regulatory commitments and maintaining the highest standards of quality and compliance across our facilities. We see significant value potential as we continue to integrate and scale the Cohance platform, and we are still at the beginning of that journey”
The company said its focus remains on meeting regulatory commitments, strengthening quality and compliance standards, and integrating and scaling the Cohance platform to unlock long-term value.
_195_291.jpg)